Industry News

Our news page will keep you informed of press releases and news articles on rapid and alternative microbiological method technologies and updates from technology suppliers.

Please click here to submit your news.

Hema Diagnostic Systems Announces the Program for Development and Design of a Multiplex Assay for Sepsis

Hema Diagnostic Systems, located in Miramar, Florida, USA, a wholly owned subsidiary of Generex Biotechnology Corporation, has announced its intention to develop a new and novel multiplex assay designed for use with Sepsis. Given the preliminary designation of RAPID 1-2-3® HEMA® SEPSIS, the team development is coordinated effort involving both Hema Diagnostic Systems and Generex Biotechnology.

Sepsis is a complex clinical syndrome of inflammatory dysregulation in response to infection. It is found primarily in hospital settings and is a major cause of disease and death in the United States and worldwide. Over 1 million people every year are afflicted by this syndrome in the US alone. It has been estimated that between 28-50% of these patients die (National Center for Health Statistics Data Brief No. 62 June 2011. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals).

Sepsis is a rapidly-developing life-threatening condition and a leading cause of hospital deaths in the US and abroad. Early assessment and management is the key to improving survival rates. Because of the rapid development and progression of sepsis, there is an unmet clinical need for a diagnostic test that will allow physicians to accurately assess at patient's status in a matter of minutes.

Using its proprietary diagnostic platform, HDS is developing a quantitative, multiplex, rapid point-of-care diagnostic assay for direct bedside use by physicians and medical personnel to evaluate a patient's current status within the sepsis syndrome. The results of this assay will be available in 15-20 minutes.

This multiplex assay will be a rapid result diagnostic tool providing physicians with quantifiable biomarker based data to assess and monitor a patient's current status and likelihood of progression within sepsis syndromes. As such, it is a multi-purpose diagnostic assay.

This assay will be based on the detection of biomarkers, usually proteins, which are normally produced in the body under sepsis conditions. The detection of multiple biomarkers in sepsis patients and their quantitation will also allow the physician to closely monitor the development of the sepsis syndrome in real-time, to aid in determining the overall effects of treatment choices, and to alter treatment, if necessary.

Post a Comment

Previous Post Next Post

Contact Form